CD8A and Epstein-Barr virus infection: Both treatments compromise CD4+ T cell help leading to a less functional CD8+ T cell phenotype (Caduff et al., 2020; McHugh et al., 2020) and compromising CD8+ T cell mediated immune control of EBV infection with no further increase of viral loads upon antibody mediated depletion of this cytotoxic T cell subset (McHugh et al., 2020).